Ethan Basch1, Karen A Autio2, Matthew R Smith3, Antonia V Bennett4, Aaron L Weitzman5, Christian Scheffold5, Christopher Sweeney6, Dana E Rathkopf7, David C Smith8, Daniel J George9, Celestia S Higano10, Andrea L Harzstark11, A Oliver Sartor12, Michael S Gordon13, Nicholas J Vogelzang14, Johann S de Bono15, Naomi B Haas16, Paul G Corn17, Frauke Schimmoller5, Howard I Scher2. 1. Cancer Outcomes Research Program, Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC, USA. Electronic address: Ebasch@med.unc.edu. 2. Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weil Cornell Medical College, New York, NY, USA. 3. Genitourinary Oncology Program, Massachusetts General Hospital, Boston, MA, USA. 4. Cancer Outcomes Research Program, Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC, USA. 5. Clinical Development, Exelixis, Inc., South San Francisco, CA, USA. 6. Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA, USA. 7. Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 8. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 9. Genitourinary Medical Oncology, Duke University Medical Center, Durham, NC, USA. 10. Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA. 11. Urologic Surgery and Oncology, University of California San Francisco, San Francisco, CA, USA. 12. Tulane Cancer Center, Tulane University, New Orleans, LA, USA. 13. Pinnacle Oncology Hematology, Scottsdale, AZ, USA. 14. Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA. 15. Drug Development Unit, Royal Marsden Hospital, Sutton, Surrey, UK. 16. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. 17. Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Abstract
BACKGROUND: Pain negatively affects quality of life for cancer patients. Preliminary data in metastatic castration-resistant prostate cancer (mCRPC) suggested a benefit of the oral tyrosine kinase inhibitor cabozantinib to pain palliation. OBJECTIVE: Prospective evaluation of cabozantinib's benefits on pain and narcotic use in mCRPC. DESIGN, SETTING, AND PARTICIPANTS: This was a nonrandomized expansion (NRE) cohort (n=144) of a phase 2 randomized discontinuation trial in docetaxel-refractory mCRPC patients. Pain and interference of symptoms with sleep and general activity were electronically self-reported daily for 7-d intervals at baseline and regularly scheduled throughout the study. Mean per-patient scores were calculated for each interval. Narcotic use was recorded daily during the same intervals. INTERVENTION: Open-label cabozantinib (100mg or 40mg). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The following stringent response definition was used: clinically meaningful pain reduction (≥30% improvement in mean scores from baseline) confirmed at a later interval without concomitant increases in narcotics. Only patients with moderate or severe baseline pain were analyzed. RESULTS AND LIMITATIONS: Sixty-five patients with moderate or severe baseline pain were evaluable. Of these, 27 (42%) experienced pain palliation according to the stringent response definition. Thirty-seven patients (57%) had clinically meaningful pain relief at two consecutive intervals, reported ≥6 wk apart in the majority. Forty-four patients (68%) had palliation at one or more intervals; 36 (55%) decreased narcotics use during one or more intervals. Clinically meaningful pain reduction was associated with significant (p ≤ 0.001) improvements in sleep quality and general activity. A limitation of this study was its open-label design. CONCLUSIONS: Cabozantinib demonstrated clinically meaningful pain palliation, reduced or eliminated patients' narcotic use, and improved patient functioning, thus meriting prospective validation in phase 3 studies. PATIENT SUMMARY: We evaluated the potential of cabozantinib to improve symptoms in patients with metastatic prostate cancer that no longer responds to standard therapies. We saw a promising reduction in pain and reduced need for narcotic painkillers. Larger, well-controlled trials are necessary to confirm these findings.
BACKGROUND:Pain negatively affects quality of life for cancerpatients. Preliminary data in metastatic castration-resistant prostate cancer (mCRPC) suggested a benefit of the oral tyrosine kinase inhibitor cabozantinib to pain palliation. OBJECTIVE: Prospective evaluation of cabozantinib's benefits on pain and narcotic use in mCRPC. DESIGN, SETTING, AND PARTICIPANTS: This was a nonrandomized expansion (NRE) cohort (n=144) of a phase 2 randomized discontinuation trial in docetaxel-refractory mCRPC patients. Pain and interference of symptoms with sleep and general activity were electronically self-reported daily for 7-d intervals at baseline and regularly scheduled throughout the study. Mean per-patient scores were calculated for each interval. Narcotic use was recorded daily during the same intervals. INTERVENTION: Open-label cabozantinib (100mg or 40mg). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The following stringent response definition was used: clinically meaningful pain reduction (≥30% improvement in mean scores from baseline) confirmed at a later interval without concomitant increases in narcotics. Only patients with moderate or severe baseline pain were analyzed. RESULTS AND LIMITATIONS: Sixty-five patients with moderate or severe baseline pain were evaluable. Of these, 27 (42%) experienced pain palliation according to the stringent response definition. Thirty-seven patients (57%) had clinically meaningful pain relief at two consecutive intervals, reported ≥6 wk apart in the majority. Forty-four patients (68%) had palliation at one or more intervals; 36 (55%) decreased narcotics use during one or more intervals. Clinically meaningful pain reduction was associated with significant (p ≤ 0.001) improvements in sleep quality and general activity. A limitation of this study was its open-label design. CONCLUSIONS:Cabozantinib demonstrated clinically meaningful pain palliation, reduced or eliminated patients' narcotic use, and improved patient functioning, thus meriting prospective validation in phase 3 studies. PATIENT SUMMARY: We evaluated the potential of cabozantinib to improve symptoms in patients with metastatic prostate cancer that no longer responds to standard therapies. We saw a promising reduction in pain and reduced need for narcotic painkillers. Larger, well-controlled trials are necessary to confirm these findings.
Authors: Andreas Varkaris; Paul G Corn; Nila U Parikh; Eleni Efstathiou; Jian H Song; Yu-Chen Lee; Ana Aparicio; Anh G Hoang; Sanchaika Gaur; Lynnelle Thorpe; Sankar N Maity; Menashe Bar Eli; Bogdan A Czerniak; Yiping Shao; Mian Alauddin; Sue-Hwa Lin; Christopher J Logothetis; Gary E Gallick Journal: Clin Cancer Res Date: 2015-08-13 Impact factor: 12.531
Authors: Atish D Choudhury; Kathryn P Gray; Jeffrey G Supko; Lauren C Harshman; Mary-Ellen Taplin; Amanda F Pace; Matthew Farina; Katherine A Zukotynski; Brandon Bernard; Philip W Kantoff; Mark Pomerantz; Christopher Sweeney Journal: Prostate Date: 2018-06-07 Impact factor: 4.104
Authors: Ethan M Basch; Mark Scholz; Johann S de Bono; Nicholas Vogelzang; Paul de Souza; Gavin Marx; Ulka Vaishampayan; Saby George; James K Schwarz; Emmanuel S Antonarakis; Joseph M O'Sullivan; Arash Rezazadeh Kalebasty; Kim N Chi; Robert Dreicer; Thomas E Hutson; Amylou C Dueck; Antonia V Bennett; Erica Dayan; Milan Mangeshkar; Jaymes Holland; Aaron L Weitzman; Howard I Scher Journal: Eur Urol Date: 2018-12-04 Impact factor: 20.096
Authors: Matthew R Smith; Christopher J Sweeney; Paul G Corn; Dana E Rathkopf; David C Smith; Maha Hussain; Daniel J George; Celestia S Higano; Andrea L Harzstark; A Oliver Sartor; Nicholas J Vogelzang; Michael S Gordon; Johann S de Bono; Naomi B Haas; Christopher J Logothetis; Aymen Elfiky; Christian Scheffold; A Douglas Laird; Frauke Schimmoller; Ethan M Basch; Howard I Scher Journal: J Clin Oncol Date: 2014-09-15 Impact factor: 44.544
Authors: Sara M Tolaney; David R Ziehr; Hao Guo; Mei R Ng; William T Barry; Michaela J Higgins; Steven J Isakoff; Jane E Brock; Elena V Ivanova; Cloud P Paweletz; Michelle K Demeo; Nikhil H Ramaiya; Beth A Overmoyer; Rakesh K Jain; Eric P Winer; Dan G Duda Journal: Oncologist Date: 2016-10-27 Impact factor: 5.837